VRT – Macquarie rates the stock as Neutral

By Broker News | More Articles by Broker News

The company has acquired the Aagaard fertility clinic in Denmark. The company will pay a maximum consideration of $16.5m, including $10.8m at completion and a $5.6m earn out in cash and scrip.

Macquarie observes, with minimal geographical synergies and a history of anaemic organic growth in the country, this acquisition offers a relatively short-lived leg up in terms of group growth. Conditions remain tough, too, on the home front.

The broker retains a Neutral rating and raises the target to $6.70 from $6.50.

Sector: Health Care Equipment & Services.

Target price is $6.70.Current Price is $5.91. Difference: $0.79 – (brackets indicate current price is over target). If VRT meets the Macquarie target it will return approximately 12% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →